Radioactive injection takes on tough pancreatic cancer in early trial

NCT ID NCT06278454

Recruiting now Disease control Sponsor: Chengdu New Radiomedicine Technology Co. LTD. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new radioactive drug called NRT6008, given alongside standard chemotherapy, for people with advanced pancreatic cancer that cannot be removed by surgery or has spread to nearby lymph nodes. The trial will enroll 58 adults to find the safest dose and check for side effects, while also watching for signs that tumors shrink. It is too early to know if this approach will work better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NRT6008 injection (a radioactive drug) plus standard chemotherapy (gemcitabine/nab-paclitaxel or FOLFIRINOX)
What this could lead to: If successful, this could lead to a new treatment option that shrinks tumors or slows progression in people with advanced pancreatic cancer that cannot be removed by surgery.
What could go wrong: This is a very early Phase I trial with only 58 participants, so the main goal is safety and finding the right dose—not yet proving it works. The radioactive drug may cause side effects like fatigue or damage to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma Lymphatic Metastasis malignant pancreatic neoplasm metastatic malignant neoplasm in the lymph nodes pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC CANCER LYMPH NODE METASTASES UNRESECTABLE PANCREATIC CANCER

Contacts and locations

Locations

Chongqing University Cancer Hospital
RECRUITING

Chongqing, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, China
Second Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, China
Shanghai Changhai Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Shanghai General Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Tianjin Medical University General Hospital
RECRUITING

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.